US 11,897,933 B2
Anti-KRAS-G12D T cell receptors
Eric Tran, Portland, OR (US); Yong-Chen Lu, Rockville, MD (US); Anna Pasetto, Stockholm (SE); Paul F. Robbins, Chevy Chase, MD (US); Steven A. Rosenberg, Potomac, MD (US); and Zhili Zheng, Gaithersburg, MD (US)
Assigned to The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Filed by The United States of America,as represented by the Secretary,Department of Health and Human Services, Bethesda, MD (US)
Filed on Jun. 11, 2021, as Appl. No. 17/345,390.
Application 16/838,395 is a division of application No. 16/321,899, granted, now 10,611,816, issued on Apr. 7, 2020, previously published as PCT/US2017/044615, filed on Jul. 31, 2017.
Application 17/345,390 is a continuation of application No. 16/838,395, filed on Apr. 2, 2020, granted, now 11,208,456.
Claims priority of provisional application 62/369,883, filed on Aug. 2, 2016.
Prior Publication US 2021/0300988 A1, Sep. 30, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/725 (2006.01); C07K 14/82 (2006.01); G01N 33/574 (2006.01); A61P 35/00 (2006.01); C12N 15/85 (2006.01); A61K 38/00 (2006.01)
CPC C07K 14/7051 (2013.01) [A61P 35/00 (2018.01); C07K 14/82 (2013.01); C12N 15/85 (2013.01); G01N 33/57407 (2013.01); A61K 38/00 (2013.01); C12N 2015/8518 (2013.01); G01N 2333/7051 (2013.01)] 35 Claims
 
1. An isolated or purified nucleic acid comprising a nucleotide sequence encoding a TCR comprising:
(i) an amino acid sequence at least 99% identical to the amino acid sequence of SEQ ID NO: 15 and an amino acid sequence at least 99% identical to the amino acid sequence of SEQ ID NO: 16;
(ii) an amino acid sequence at least 99% identical to the amino acid sequence of SEQ ID NO: 23 and an amino acid sequence at least 99% identical to the amino acid sequence of SEQ ID NO: 24;
(iii) an amino acid sequence at least 99% identical to the amino acid sequence of SEQ ID NO: 31 and an amino acid sequence at least 99% identical to the amino acid sequence of SEQ ID NO: 32;
(iv) an amino acid sequence at least 99% identical to the amino acid sequence of SEQ ID NO: 39 and an amino acid sequence at least 99% identical to the amino acid sequence of SEQ ID NO: 40;
(v) an amino acid sequence at least 99% identical to amino acids 20-129 of SEQ ID NO: 15 and an amino acid sequence at least 99% identical to amino acids 22-133 of SEQ ID NO: 16;
(vi) an amino acid sequence at least 99% identical to amino acids 20-129 of SEQ ID NO: 23 and an amino acid sequence at least 99% identical to amino acids 22-133 of SEQ ID NO: 24;
(vii) an amino acid sequence at least 99% identical to amino acids 20-129 of SEQ ID NO: 31 and an amino acid sequence at least 99% identical to amino acids 22-133 of SEQ ID NO: 32; or
(viii) an amino acid sequence at least 99% identical to amino acids 21-132 of SEQ ID NO: 39 and an amino acid sequence at least 99% identical to amino acids 22-130 of SEQ ID NO: 40.